Figures & data
Table 1 Risk reduction in stroke and bleeding eventsTable Footnote* using NOACs compared with warfarin
Figure 1 Different cost perspectives in oral anticoagulant therapy.
![Figure 1 Different cost perspectives in oral anticoagulant therapy.](/cms/asset/af63656a-8dd7-4b33-840d-681a93b4619f/dceo_a_145813_f0001_b.jpg)
Figure 2 Annual costs per NVAF patient receiving warfarin versus dabigatran 110 mg and 150 mg (US$).**
Abbreviation: NVAF, nonvalvular atrial fibrillation.
![Figure 2 Annual costs per NVAF patient receiving warfarin versus dabigatran 110 mg and 150 mg (US$).**](/cms/asset/c15d0fd3-dbd1-4076-bd9f-5b9d3fa9ab56/dceo_a_145813_f0002_b.jpg)
Figure 3 Annual costs per NVAF patient receiving warfarin versus rivaroxaban 20 mg (US$).**
Abbreviation: NVAF, nonvalvular atrial fibrillation.
![Figure 3 Annual costs per NVAF patient receiving warfarin versus rivaroxaban 20 mg (US$).**](/cms/asset/d2109e23-232f-4698-817f-12a78f11723b/dceo_a_145813_f0003_b.jpg)
Figure 4 Annual costs per NVAF patient receiving warfarin versus apixaban 5 mg (US$).**
Abbreviation: NVAF, nonvalvular atrial fibrillation.
![Figure 4 Annual costs per NVAF patient receiving warfarin versus apixaban 5 mg (US$).**](/cms/asset/b6649c8f-5940-43a9-b664-148a79fd0dbf/dceo_a_145813_f0004_b.jpg)
Figure 5 Annual costs per NVAF patient receiving warfarin versus edoxaban 60 mg (US$).**
Abbreviation: NVAF, nonvalvular atrial fibrillation.
![Figure 5 Annual costs per NVAF patient receiving warfarin versus edoxaban 60 mg (US$).**](/cms/asset/3f5fea0e-bd03-4fa0-80ac-29deafb9b1b6/dceo_a_145813_f0005_b.jpg)
Table 2 Annual average costs of INR monitoring of warfarin patients (US$)
Table 3 Total extra costs of first-incident stroke and first-incident bleeding events in AF patients – 3-year present values (US$)